127 related articles for article (PubMed ID: 36281138)
21. The optimal immunosuppressive therapy for aplastic anemia.
Shin SH; Lee JW
Int J Hematol; 2013 May; 97(5):564-72. PubMed ID: 23605367
[TBL] [Abstract][Full Text] [Related]
22. PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis.
Tu J; Pan H; Li R; Wang Z; Lian Y; Li W; Shi J; Fang L
Acta Haematol; 2021; 144(1):34-43. PubMed ID: 32877903
[TBL] [Abstract][Full Text] [Related]
23. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
[TBL] [Abstract][Full Text] [Related]
24. ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis.
Gafter-Gvili A; Ram R; Gurion R; Paul M; Yeshurun M; Raanani P; Shpilberg O
Acta Haematol; 2008; 120(4):237-43. PubMed ID: 19246887
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia.
Deyell RJ; Shereck EB; Milner RA; Schultz KR
Pediatr Hematol Oncol; 2011 Sep; 28(6):469-78. PubMed ID: 21707222
[TBL] [Abstract][Full Text] [Related]
26. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressive therapy in severe aplastic anemia.
Patel BA; Townsley DM; Scheinberg P
Semin Hematol; 2022 Jan; 59(1):21-29. PubMed ID: 35491055
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
29. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.
Yu R; Zhang S; Zhao D; Yuan Z
Expert Rev Mol Med; 2022 Jan; 24():e5. PubMed ID: 34986905
[TBL] [Abstract][Full Text] [Related]
31. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.
Peinemann F; Grouven U; Kröger N; Bartel C; Pittler MH; Lange S
PLoS One; 2011 Apr; 6(4):e18572. PubMed ID: 21541024
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.
Kim SY; Le Rademacher J; Antin JH; Anderlini P; Ayas M; Battiwalla M; Carreras J; Kurtzberg J; Nakamura R; Eapen M; Deeg HJ
Haematologica; 2014 Dec; 99(12):1868-75. PubMed ID: 25107891
[TBL] [Abstract][Full Text] [Related]
33. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia.
Scheinberg P; Cooper JN; Sloand EM; Wu CO; Calado RT; Young NS
JAMA; 2010 Sep; 304(12):1358-64. PubMed ID: 20858879
[TBL] [Abstract][Full Text] [Related]
34. Late clonal diseases of treated aplastic anemia.
Socié G; Rosenfeld S; Frickhofen N; Gluckman E; Tichelli A
Semin Hematol; 2000 Jan; 37(1):91-101. PubMed ID: 10676914
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
36. Management of aplastic anemia: the role of systematic reviews and meta-analyses.
Gafter-Gvili A; Ram R; Raanani P; Shpilberg O
Acta Haematol; 2011; 125(1-2):47-54. PubMed ID: 21150187
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials.
Zhang XT; Zhang YN; Zhu JJ; Wang X; Cao J; Chen W; Qi N; Xu KL; Cheng H
Hematology; 2022 Dec; 27(1):733-741. PubMed ID: 35688457
[TBL] [Abstract][Full Text] [Related]
38. First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.
Hu J; Zhang L; Zhao X; Liu X; Jing L; Zhou K; Li Y; Li Y; Li J; Ye L; Peng G; Fan H; Yang W; Yang Y; Xiong Y; Song L; Zhang F
Ann Hematol; 2022 Nov; 101(11):2405-2412. PubMed ID: 36151352
[TBL] [Abstract][Full Text] [Related]
39. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.
Frickhofen N; Heimpel H; Kaltwasser JP; Schrezenmeier H;
Blood; 2003 Feb; 101(4):1236-42. PubMed ID: 12393680
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
